Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …

Purpose Although rituximab (R) is commonly used for patients with advanced follicular
lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to …

Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis
of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current …

Purpose R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and
prednisone) and R-CVP (rituximab with cyclophosphamide, vincristine and prednisone) …

Purpose To compare the long-term outcome of patients with previously untreated follicular
lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

Background The natural history of follicular lymphoma is believed not to have changed over
the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is …

The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several
standard treatment options for advanced follicular lymphoma. This, like similar …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

BACKGROUND. It is unclear whether new treatment modalities have improved the survival
of follicular lymphoma patients. Some data show that there has been no improvement in …